A Woburn biotechnology company is now facing a significantly larger wave of layoffs than initially disclosed — with state filings suggesting between 161 and 224 Massachusetts employees are on the chopping block after federal regulators rejected its lead cancer treatment for the second time.
Replimune Group, Inc. did not respond to multiple requests for comment on the scope of the cuts.
According to Worker Adjustment and Retraining Notification filings, the company initially disclosed 63 layoffs at its Woburn headquarters, effective April 13 through April 24…